Similar effectiveness of the inactivated vaccine BBIBP-CorV (Sinopharm) and the mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19 related hospitalizations during the Delta outbreak in the UAE
Mira Mousa, Mohammed Albreiki, Fatima Alshehhi, Safiya AlShamsi, Nada Al Marzouqi, Tayba Alawadi, Hussain Alrand, Habiba Alsafar, Asma Fikri
Abstract
Inactivated vaccine BBIBP-CorV {Sinopharm; 95% [95% confidence interval (CI): 94, 97%]} and the mRNA vaccine BNT162b2 [Pfizer-BioNTech; 98% (95% CI: 86, 99%)] demonstrated protection against COVID-19 related hospitalizations from the Delta (B.1.617.2) variant. Ongoing efforts are necessary to target vaccine hesitancy and to promote booster shots for protection against severe COVID-19 disease and arising variants of concern.
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)OutbreakBooster (rocketry)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakBooster doseVirologyVaccinationConfidence intervalPediatricsInternal medicineInfectious disease (medical specialty)DiseaseVirusTiterPhysicsAstronomySARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyCOVID-19 Clinical Research Studies